Helpful Materials About Ph+ CML and TASIGNA
INFORMATION TO HELP YOU START TASIGNA AND STAY ON TRACK.
The resources below provide information about Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) and TASIGNA® (nilotinib) capsules. You may find it helpful to download these guides.
Below the list of downloadable materials, you’ll find organizations and groups that are involved in Ph+ CML.
TASIGNA Guide for Newly Diagnosed Patients
Created for newly diagnosed patients, this guide provides education about Ph+ CML-CP, treatment milestones, and discusses why TASIGNA may be an option for your first medication.
TASIGNA Patient Guide
Whether you’re newly diagnosed with Ph+ CML-CP or you’re switching from another medication to TASIGNA, this guide provides helpful background on the disease and your treatment.
TASIGNA Treatment Guide
Get information on how to take TASIGNA and blood tests your doctor may order. You’ll also have a place to record the results of your blood work.
TASIGNA Medication Guide
This guide lists Important Safety Information about TASIGNA.
Doctor Discussion Guide for Newly Diagnosed Patients
If you’re a newly diagnosed patient, explore if TASIGNA is an option as you begin your treatment journey.
Doctor Discussion Guide for patients switching
If your current treatment doesn’t seem to be working, here are questions to ask your doctor to see if it may be time to switch to TASIGNA.
Managing and Monitoring Ph+ CML
Learn about your condition and the treatment milestones your doctor may discuss with you.
Connect with others who have Ph+ CML
Some of the more common forms of cancer get a lot of attention. Ph+ CML, on the other hand, is considered a rare cancer. That’s all the more reason to reach out to people like you who are living with the disease. The organizations listed below may be a helpful source of connections, information, and support.
National Cancer Institute’s Cancer Information Service
1-800-4CANCER (1-800-422-6237)
Those with TTY equipment may call 1-800-332-8615
The organizations and websites listed on this page are maintained by third parties over whom Novartis Pharmaceuticals Corporation has no control. As such, Novartis Pharmaceuticals Corporation makes no representation as to the accuracy or any other aspect of the information supplied by these organizations or contained in these websites.
